Dogwood (DWTX) Therapeutics announced that dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP, evaluating Halneuron to treat neuropathic pain associated with prior chemotherapy treatment is expected to occur in the first quarter of 2025.